Although the past two decades have seen considerable advances in the treatment of MM with the introduction of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies such as Elotuzumab and Daratumumab that target signaling lymphocytic activation molecule F7 (SLAMF7) and CD38, respectively [1], MM still remains incurable with most patients eventually succumbing to the disease [2,3]. This evidence concerns the gene CD38 and Miyoshi myopathy.